Precision Oncology Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Precision Oncology Market
5.1. COVID-19 Landscape: Precision Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Precision Oncology Market, By Product type
8.1. Precision Oncology Market, by Product type, 2024-2033
8.1.1 Diagnostics
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Therapeutics
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Precision Oncology Market, By Cancer type
9.1. Precision Oncology Market, by Cancer type, 2024-2033
9.1.1. Breast cancer
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Colorectal cancer
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Cervical cancer
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Prostate cancer
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Lung cancer
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.5. Other cancers
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Precision Oncology Market, By End use
10.1. Precision Oncology Market, by End use, 2024-2033
10.1.1. Hospitals & Diagnostic Laboratories
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Pharmaceutical & Biotechnology companies
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Healthcare data companies
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Precision Oncology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product type (2021-2033)
11.1.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.1.3. Market Revenue and Forecast, by End use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product type (2021-2033)
11.2.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.2.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product type (2021-2033)
11.3.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.3.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product type (2021-2033)
11.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product type (2021-2033)
11.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End use (2021-2033)
Chapter 12. Company Profiles
12.1. F Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Thermo Fisher Scientific Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Invitae Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bristol-Myers Squibb
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. QIAGEN
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Illumina, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Quest Diagnostics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Laboratory Corporation of America Holdings
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers